TY - JOUR AU - Nam, J. L. AU - Ramiro, S. AU - Gaujoux-Viala, C. AU - Takase, K. AU - Leon-Garcia, M. AU - Emery, P. PY - 2014 DA - 2014// TI - Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis JO - Ann Rheum Dis VL - 73 UR - https://doi.org/10.1136/annrheumdis-2013-204577 DO - 10.1136/annrheumdis-2013-204577 ID - Nam2014 ER - TY - JOUR AU - Bergstra, S. A. AU - Branco, J. C. AU - Vega-Morales, D. AU - Salomon-Escoto, K. AU - Govind, N. AU - Allaart, C. F. PY - 2018 DA - 2018// TI - Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry JO - Ann Rheum Dis VL - 77 ID - Bergstra2018 ER - TY - JOUR AU - Putrik, P. AU - Ramiro, S. AU - Kvien, T. K. AU - Sokka, T. AU - Pavlova, M. AU - Uhlig, T. PY - 2014 DA - 2014// TI - Inequities in access to biologic and synthetic DMARDs across 46 European countries JO - Ann Rheum Dis VL - 73 UR - https://doi.org/10.1136/annrheumdis-2012-202603 DO - 10.1136/annrheumdis-2012-202603 ID - Putrik2014 ER - TY - JOUR AU - Putrik, P. AU - Ramiro, S. AU - Kvien, T. K. AU - Sokka, T. AU - Uhlig, T. AU - Boonen, A. PY - 2014 DA - 2014// TI - Equity in Clinical Eligibility Criteria for RA treatment Working Group. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country’s wealth? JO - Ann Rheum Dis VL - 73 UR - https://doi.org/10.1136/annrheumdis-2013-203819 DO - 10.1136/annrheumdis-2013-203819 ID - Putrik2014 ER - TY - JOUR AU - Haustein, R. AU - Millas, C. AU - Höer, A. AU - Häussler, B. PY - 2012 DA - 2012// TI - Saving money in the European healthcare systems with biosimilars JO - GaBI J VL - 1 UR - https://doi.org/10.5639/gabij.2012.0103-4.036 DO - 10.5639/gabij.2012.0103-4.036 ID - Haustein2012 ER - TY - JOUR AU - Jha, A. AU - Upton, A. AU - Dunlop, W. C. N. AU - Akehurst, R. PY - 2015 DA - 2015// TI - The budget impact of biosimilar infliximab (Remsima®) for the treatment of autoimmune diseases in five European countries JO - Adv Ther VL - 32 UR - https://doi.org/10.1007/s12325-015-0233-1 DO - 10.1007/s12325-015-0233-1 ID - Jha2015 ER - TY - JOUR AU - Lis, K. AU - Kuzawińska, O. AU - Bałkowiec-Iskra, E. PY - 2014 DA - 2014// TI - Tumor necrosis factor inhibitors - state of knowledge JO - Arch Med Sci VL - 10 UR - https://doi.org/10.5114/aoms.2014.47827 DO - 10.5114/aoms.2014.47827 ID - Lis2014 ER - TY - JOUR AU - Tracey, D. AU - Klareskog, L. AU - Sasso, E. H. AU - Salfeld, J. G. AU - Tak, P. P. PY - 2008 DA - 2008// TI - Tumor necrosis factor antagonist mechanisms of action: a comprehensive review JO - Pharmacol Ther VL - 117 UR - https://doi.org/10.1016/j.pharmthera.2007.10.001 DO - 10.1016/j.pharmthera.2007.10.001 ID - Tracey2008 ER - TY - JOUR AU - Matsuno, H. AU - Yudoh, K. AU - Katayama, R. AU - Nakazawa, F. AU - Uzuki, M. AU - Sawai, T. PY - 2002 DA - 2002// TI - The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera JO - Rheumatology. VL - 41 UR - https://doi.org/10.1093/rheumatology/41.3.329 DO - 10.1093/rheumatology/41.3.329 ID - Matsuno2002 ER - TY - JOUR AU - Murray, K. M. AU - Dahl, S. L. PY - 1997 DA - 1997// TI - Recombinant human tumor necrosis factor receptor (p75) fc fusion protein (tnfr:Fc) in rheumatoid arthritis JO - Ann Pharmacother VL - 31 UR - https://doi.org/10.1177/106002809703101111 DO - 10.1177/106002809703101111 ID - Murray1997 ER - TY - JOUR AU - Scott, L. J. PY - 2014 DA - 2014// TI - Etanercept: a review of its use in autoimmune inflammatory diseases JO - Drugs. VL - 74 UR - https://doi.org/10.1007/s40265-014-0258-9 DO - 10.1007/s40265-014-0258-9 ID - Scott2014 ER - TY - STD TI - Han-soo L. LG Chem wins sales approval for LBEC0101 in Japan. http://www.koreabiomed.com/news/articleView.html?idxno=2391. Accessed 27 Nov 2018. UR - http://www.koreabiomed.com/news/articleView.html?idxno=2391 ID - ref12 ER - TY - STD TI - The Center for Biosimilars Staff. Eye on Pharma: LG Chem’s etanercept biosimilar gains Korean approval. https://www.centerforbiosimilars.com/news/eye-on-pharma-lg-chems-etanercept-biosimilar-gains-korean-approval. Accessed 27 Nov 2018. UR - https://www.centerforbiosimilars.com/news/eye-on-pharma-lg-chems-etanercept-biosimilar-gains-korean-approval ID - ref13 ER - TY - STD TI - Generics and Biosimilars Initiative. Guidelines for biosimilars around the world. http://www.gabionline.net/Reports/Guidelines-for-biosimilars-around-the-world. Accessed 9 Sept 2018. UR - http://www.gabionline.net/Reports/Guidelines-for-biosimilars-around-the-world ID - ref14 ER - TY - STD TI - European Medicines Agency. Guideline on similar biological medicinal products. CHMP/437/04 Rev 1. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. Accessed 9 Sept 2018. UR - http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf ID - ref15 ER - TY - JOUR AU - Schulze-Koops, H. AU - Skapenko, A. PY - 2017 DA - 2017// TI - Biosimilars in rheumatology: a review of the evidence and their place in the treatment algorithm JO - Rheumatology (Oxford) VL - 56 UR - https://doi.org/10.1093/rheumatology/kex277 DO - 10.1093/rheumatology/kex277 ID - Schulze-Koops2017 ER - TY - JOUR AU - Emery, P. AU - Vencovský, J. AU - Sylwestrzak, A. AU - Leszczyński, P. AU - Porawska, W. AU - Baranauskaite, A. PY - 2017 DA - 2017// TI - A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy JO - Ann Rheum Dis VL - 76 UR - https://doi.org/10.1136/annrheumdis-2015-207588 DO - 10.1136/annrheumdis-2015-207588 ID - Emery2017 ER - TY - JOUR AU - Emery, P. AU - Vencovský, J. AU - Sylwestrzak, A. AU - Leszczyński, P. AU - Porawska, W. AU - Stasiuk, B. PY - 2017 DA - 2017// TI - Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4 JO - Ann Rheum Dis VL - 76 UR - https://doi.org/10.1136/annrheumdis-2017-211591 DO - 10.1136/annrheumdis-2017-211591 ID - Emery2017 ER - TY - JOUR AU - Weinblatt, M. E. AU - Baranauskaite, A. AU - Dokoupilova, E. AU - Zielinska, A. AU - Jaworski, J. AU - Racewicz, A. PY - 2018 DA - 2018// TI - Switching from reference Adalimumab to SB5 (adalimumab biosimilar) in patients with rheumatoid arthritis: fifty-two-week phase III randomized study results JO - Arthritis Rheumatol VL - 70 UR - https://doi.org/10.1002/art.40444 DO - 10.1002/art.40444 ID - Weinblatt2018 ER - TY - JOUR AU - Yoo, D. H. AU - Prodanovic, N. AU - Jaworski, J. AU - Miranda, P. AU - Ramiterre, E. AU - Lanzon, A. PY - 2017 DA - 2017// TI - Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study JO - Ann Rheum Dis VL - 76 UR - https://doi.org/10.1136/annrheumdis-2015-208786 DO - 10.1136/annrheumdis-2015-208786 ID - Yoo2017 ER - TY - JOUR AU - Cohen, S. B. AU - Burgos-Vargas, R. AU - Emery, P. AU - Jin, B. AU - Cronenberger, C. AU - Vázquez-Abad, M. D. PY - 2018 DA - 2018// TI - Extension study of PF-05280586, a potential rituximab biosimilar, versus rituximab in subjects with active rheumatoid arthritis JO - Arthritis Care Res VL - 70 UR - https://doi.org/10.1002/acr.23586 DO - 10.1002/acr.23586 ID - Cohen2018 ER - TY - JOUR AU - Lee, H. e. e. c. h. a. n. AU - Chung, H. y. e. w. o. n. AU - Lee, S. e. u. n. g. H. w. a. n. AU - Lee, H. o. w. a. r. d. AU - Yang, S. u. n. g. M. o. AU - Yoon, S. e. o. H. y. u. n. AU - Cho, J. o. o. -. Y. o. u. n. AU - Jang, I. n. -. J. i. n. AU - Yu, K. y. u. n. g. -. S. a. n. g. PY - 2017 DA - 2017// TI - LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male Subjects JO - BioDrugs VL - 31 UR - https://doi.org/10.1007/s40259-017-0230-9 DO - 10.1007/s40259-017-0230-9 ID - Lee2017 ER - TY - JOUR AU - Matsuno, H. AU - Tomomitsu, M. AU - Hagino, A. AU - Shin, S. AU - Lee, J. AU - Song, Y. W. PY - 2018 DA - 2018// TI - Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate JO - Ann Rheum Dis VL - 77 UR - https://doi.org/10.1136/annrheumdis-2017-212172 DO - 10.1136/annrheumdis-2017-212172 ID - Matsuno2018 ER - TY - JOUR AU - Jaber, A. AU - Bozzato, G. B. AU - Vedrine, L. AU - Prais, W. A. AU - Berube, J. AU - Laurent, P. E. PY - 2008 DA - 2008// TI - A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis JO - BMC Neurol VL - 8 UR - https://doi.org/10.1186/1471-2377-8-38 DO - 10.1186/1471-2377-8-38 ID - Jaber2008 ER - TY - JOUR AU - Glenski, S. AU - Conner, J. PY - 2009 DA - 2009// TI - 29 gauge needles improve patient satisfaction over 27 gauge needles for daily glatiramer acetate injections JO - Drug Healthc Patient Saf VL - 1 UR - https://doi.org/10.2147/DHPS.S8495 DO - 10.2147/DHPS.S8495 ID - Glenski2009 ER - TY - JOUR AU - Barlas, S. PY - 2017 DA - 2017// TI - FDA guidance on biosimilar interchangeability elicits diverse views JO - P T VL - 42 ID - Barlas2017 ER - TY - JOUR AU - Tweehuysen, L. AU - Bemt, B. J. F. AU - Ingen, I. L. AU - Jong, A. J. L. AU - Laan, W. H. AU - Hoogen, F. H. J. PY - 2018 DA - 2018// TI - Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab JO - Arthritis Rheumatol. VL - 70 UR - https://doi.org/10.1002/art.40324 DO - 10.1002/art.40324 ID - Tweehuysen2018 ER - TY - STD TI - Germain V, Scherlinger M, Barnetche T, Schaeverbeke T, Fédération Hospitalouniversitaire ACRONIM. Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of the nocebo effect. Ann Rheum Dis. 2018. https://doi.org/10.1136/annrheumdis-2018-214374. ID - ref28 ER - TY - STD TI - Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product—guidance for industry: draft guidance. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM537135.pdf. Accessed 27 Nov 2018. UR - http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM537135.pdf ID - ref29 ER - TY - JOUR AU - Kay, J. AU - Schoels, M. M. AU - Dörner, T. AU - Emery, P. AU - Kvien, T. K. AU - Smolen, J. S. PY - 2018 DA - 2018// TI - Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases JO - Ann Rheum Dis VL - 77 UR - https://doi.org/10.1136/annrheumdis-2017-211937 DO - 10.1136/annrheumdis-2017-211937 ID - Kay2018 ER -